Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Aetna CEO
March 22, 2019 at 08:57 AM EDT
Former Aetna Chairman and CEO Mark Bertolini says investors currently are trading "on a basis that says, 'does this drug work today? Did this trial pass today?''"
